Optura Raises “7.5M to Measure Healthcare AI ROI and Performance – Image for illustrative purposes only (Image credits: Pexels)
Optura, an enterprise platform focused on healthcare operations, has closed a $17.5 million Series A round led by Salesforce Ventures. The round brings the company’s total funding above $25 million and centers on a new discipline called ROAI, or Return on AI Investment. The move comes as health systems and insurers confront mounting pressure to show concrete results from the billions they have already poured into artificial intelligence tools.
The Scale of the Challenge
Healthcare organizations now direct nearly half of their technology investment toward AI, yet most initiatives still lack a reliable way to track whether those dollars deliver results. Industry estimates place this year’s total AI spending above $18 billion, but roughly 95 percent of enterprise generative AI pilots have so far failed to produce measurable value. Optura’s platform is already in use at major health plans and providers, including Independence Blue Cross and Ardent Health, where more than $2 billion in AI projects are now under active tracking.
Leaders describe the situation as an “AI results problem” rather than an adoption problem. Many organizations find themselves managing a growing list of disconnected point solutions without a shared framework for judging success or failure. The absence of such a framework has left executives exposed when budgets tighten or when new foundational models enter the market.
Turning Existing Workflows Into Measurable Agents
Optura converts leadership priorities into operational AI agents that are built directly from an organization’s current workflows and standard operating procedures. The system first maps fragmented data sources into a single knowledge layer that grounds every recommendation in actual operations. Use cases are then scored against three factors: organizational cost, technical readiness, and strategic priority.
Before any capital is committed, executives can run simulations that project expected returns. Once agents are deployed, live dashboards compare real-time outcomes against those original projections. The approach is designed to reduce the risk of chasing hype without a clear path to accountability.
Investor Backing Signals a Market Shift
Salesforce Ventures and Echo Health Ventures led the round, reflecting growing investor interest in tools that move healthcare AI beyond experimentation. Katie Thiry, managing director at Salesforce Ventures, noted that Optura helps customers shift from broad testing to the delivery of measurable business outcomes. Co-founder and CEO Andy Fanning has warned that the rising cost of foundational models such as Claude for Healthcare makes undisciplined spending an existential risk for many organizations.
Early results at Independence Blue Cross illustrate the potential impact. The platform has already identified $120 million in tracked value, corresponding to a 700 percent ROAI on initiatives still in flight. Those figures give health plan leaders a concrete basis for deciding which projects to expand and which to scale back.
What Comes Next for Health Systems
Optura’s framework is intended to give C-suite teams a single view of how AI investments align with member outcomes and financial targets. As more organizations adopt similar discipline, the industry may move away from the current pattern of scattered pilots toward a smaller set of initiatives that can be defended with data. The company’s early traction suggests that demand for such accountability tools is rising quickly among both payers and providers.
